NO20081074L - Macrocyclisk inhibitorer av hepatitis C-virus - Google Patents

Macrocyclisk inhibitorer av hepatitis C-virus

Info

Publication number
NO20081074L
NO20081074L NO20081074A NO20081074A NO20081074L NO 20081074 L NO20081074 L NO 20081074L NO 20081074 A NO20081074 A NO 20081074A NO 20081074 A NO20081074 A NO 20081074A NO 20081074 L NO20081074 L NO 20081074L
Authority
NO
Norway
Prior art keywords
hepatitis
virus
inhibitors
macrocyclic inhibitors
hcv
Prior art date
Application number
NO20081074A
Other languages
English (en)
Norwegian (no)
Inventor
Herman Augustinus De Kock
Kenneth Alan Simmen
Pierre Jean-Marie Bernard Raboisson
Karl Magnus Nilsson
Bengt Bertil Samuelsson
Asa Annicka Kristin Rosenquist
Mats Stefan Lindstrom
Pia Cecilia Kahnberg
Dmitry Antonov
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of NO20081074L publication Critical patent/NO20081074L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20081074A 2005-07-29 2008-02-29 Macrocyclisk inhibitorer av hepatitis C-virus NO20081074L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05107066 2005-07-29
EP06101278 2006-02-03
PCT/EP2006/064812 WO2007014918A1 (fr) 2005-07-29 2006-07-28 Inhibiteurs macrocycliques du virus de l'hepatite c

Publications (1)

Publication Number Publication Date
NO20081074L true NO20081074L (no) 2008-04-29

Family

ID=37102945

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081074A NO20081074L (no) 2005-07-29 2008-02-29 Macrocyclisk inhibitorer av hepatitis C-virus

Country Status (32)

Country Link
US (1) US8008251B2 (fr)
EP (1) EP1913014B1 (fr)
JP (1) JP5508713B2 (fr)
KR (1) KR101321392B1 (fr)
CN (1) CN101233147B (fr)
AR (1) AR054881A1 (fr)
AT (1) ATE496934T1 (fr)
AU (1) AU2006274857B2 (fr)
BR (1) BRPI0614515A2 (fr)
CA (1) CA2616954C (fr)
CY (1) CY1112001T1 (fr)
DE (1) DE602006019879D1 (fr)
DK (1) DK1913014T3 (fr)
EA (1) EA200800485A1 (fr)
GT (1) GT200600340A (fr)
HK (1) HK1116503A1 (fr)
HR (1) HRP20110289T1 (fr)
IL (1) IL188281A (fr)
ME (1) ME01233B (fr)
MX (1) MX2008001394A (fr)
MY (1) MY139987A (fr)
NO (1) NO20081074L (fr)
NZ (1) NZ564542A (fr)
PE (1) PE20070210A1 (fr)
PL (1) PL1913014T3 (fr)
PT (1) PT1913014E (fr)
RS (1) RS51776B (fr)
SG (1) SG163610A1 (fr)
SI (1) SI1913014T1 (fr)
TW (1) TWI437993B (fr)
UY (1) UY29702A1 (fr)
WO (1) WO2007014918A1 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
JP4902361B2 (ja) 2004-01-30 2012-03-21 メディヴィル・アクチエボラーグ Ｈｃｖｎｓ−３セリンプロテアーゼインヒビター
US20090074815A1 (en) * 2005-04-22 2009-03-19 Sciclone Pharmaceuticals, Inc. Immunomodulator Compounds as Vaccine Enhancers
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7935670B2 (en) 2006-07-11 2011-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8637663B2 (en) * 2006-11-17 2014-01-28 Janssen R&D Ireland Macrocyclic inhibitors of hepatitis C virus
US8383583B2 (en) 2007-10-26 2013-02-26 Enanta Pharmaceuticals, Inc. Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
BRPI0908021A2 (pt) 2008-02-04 2015-07-21 Idenix Pharmaceuticals Inc Composto, composição farmacêutica, e, usos do composto ou da composição farmacêutica
CA2719008A1 (fr) 2008-03-20 2009-09-24 Enanta Pharmaceuticals, Inc. Composes macrocycliques fluores en tant qu'inhibiteurs du virus de l'hepatite c
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102046648A (zh) 2008-05-29 2011-05-04 百时美施贵宝公司 丙型肝炎病毒抑制剂
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW201040181A (en) 2009-04-08 2010-11-16 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
TW201117812A (en) 2009-08-05 2011-06-01 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
WO2012109398A1 (fr) 2011-02-10 2012-08-16 Idenix Pharmaceuticals, Inc. Inhibiteurs macrocycliques de sérine protéase, compositions pharmaceutiques les contenant et leur utilisation pour le traitement des infections par le vhc
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9207002B2 (en) 2011-10-12 2015-12-08 International Business Machines Corporation Contaminant separator for a vapor-compression refrigeration apparatus
AU2012392557B2 (en) 2012-10-19 2017-06-01 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914613B1 (fr) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914614B1 (fr) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
WO2014137869A1 (fr) 2013-03-07 2014-09-12 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU659575B2 (en) 1992-12-29 1995-05-18 Abbvie Inc. Retroviral protease inhibiting compounds
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
AU723730B2 (en) 1996-04-23 2000-09-07 Vertex Pharmaceuticals Incorporated Urea derivatives as inhibitors of IMPDH enzyme
NZ335276A (en) 1996-10-18 2000-09-29 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus (HCV) NS3 (Non Structural Protein 3) protease
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
DK0966465T3 (da) 1997-03-14 2003-10-20 Vertex Pharma Inhibitorer af IMPDH-enzymer
CA2294562C (fr) 1997-08-11 2005-07-26 Boehringer Ingelheim (Canada) Ltd. Analogues de peptides inhibiteurs de l'hepatite c
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
EE200100492A (et) 1999-03-19 2002-12-16 Vertex Pharmaceuticals Incorporated Ensüümi IMPDH inhibiitorid
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US6867185B2 (en) * 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
JP2005535574A (ja) 2002-04-11 2005-11-24 バーテックス　ファーマシューティカルズ　インコーポレイテッド セリンプロテアーゼ、特にｈｃｖｎｓ３−ｎｓ４ａプロテアーゼのインヒビター
US20050075279A1 (en) * 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
ES2386161T3 (es) * 2003-04-16 2012-08-10 Bristol-Myers Squibb Company Proceso para separar una mezcla de enantiómeros de éster alquílico usando una enzima
US7125845B2 (en) * 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
MXPA06003141A (es) * 2003-09-22 2006-06-05 Boehringer Ingelheim Int Peptidos macrociclicos activos contra el virus de la hepatitis c.
JP4902361B2 (ja) * 2004-01-30 2012-03-21 メディヴィル・アクチエボラーグ Ｈｃｖｎｓ−３セリンプロテアーゼインヒビター
BRPI0614621A2 (pt) * 2005-07-29 2011-04-12 Tibotec Pharm Ltd inibidores macrocìclicos de vìrus da hepatite c
PL1919904T3 (pl) * 2005-07-29 2014-06-30 Janssen R&D Ireland Makrocykliczne inhibitory wirusa zapalenia wątroby typu C
CN101273038A (zh) * 2005-07-29 2008-09-24 美迪维尔公司 丙型肝炎病毒的大环化合物抑制剂
PE20070211A1 (es) * 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c

Also Published As

Publication number Publication date
BRPI0614515A2 (pt) 2011-03-29
AU2006274857B2 (en) 2012-11-29
EP1913014B1 (fr) 2011-01-26
PL1913014T3 (pl) 2011-06-30
SI1913014T1 (sl) 2011-06-30
EA200800485A1 (ru) 2009-04-28
US20080200503A1 (en) 2008-08-21
HRP20110289T1 (hr) 2011-05-31
MX2008001394A (es) 2008-04-08
KR101321392B1 (ko) 2013-10-30
TW200801044A (en) 2008-01-01
PE20070210A1 (es) 2007-04-16
CA2616954A1 (fr) 2007-02-08
AR054881A1 (es) 2007-07-25
JP5508713B2 (ja) 2014-06-04
ME01233B (fr) 2013-06-20
NZ564542A (en) 2010-03-26
KR20080039430A (ko) 2008-05-07
PT1913014E (pt) 2011-04-20
UY29702A1 (es) 2007-05-31
DE602006019879D1 (de) 2011-03-10
EP1913014A1 (fr) 2008-04-23
US8008251B2 (en) 2011-08-30
DK1913014T3 (da) 2011-08-01
CY1112001T1 (el) 2015-11-04
JP2009502881A (ja) 2009-01-29
AU2006274857A1 (en) 2007-02-08
CN101233147B (zh) 2012-06-20
ATE496934T1 (de) 2011-02-15
IL188281A (en) 2015-01-29
CA2616954C (fr) 2013-12-24
GT200600340A (es) 2007-02-26
RS51776B (en) 2011-12-31
MY139987A (en) 2009-11-30
IL188281A0 (en) 2008-04-13
SG163610A1 (en) 2010-08-30
WO2007014918A1 (fr) 2007-02-08
CN101233147A (zh) 2008-07-30
TWI437993B (zh) 2014-05-21
HK1116503A1 (en) 2008-12-24

Similar Documents

Publication Publication Date Title
NO20081074L (no) Macrocyclisk inhibitorer av hepatitis C-virus
CA2616580A1 (fr) Inhibiteurs macrocycliques du virus de l'hepatite c
NO20081071L (no) Makrocykliske inhibitorer av hepatitt C virus
EA200970493A1 (ru) Макроциклические ингибиторы вируса гепатита с
TW200745118A (en) Macrocylic inhibitors of hepatitis C virus
TW200740775A (en) Macrocylic inhibitors of hepatitis C virus
PE20090630A1 (es) Derivados de indol 2-carboxi sustituidos y metodos para su utilizacion
AP1753A (en) Thiophene derivatives as antiviral agents for flavvivirus infection
TW200800949A (en) Macrocylic inhibitors of hepatitis C virus
TW200639169A (en) Bicyclic heteroaryl derivatives for treating viruses
NO20080879L (no) HCV-NS3-proteaseinhibitorer
NO20082496L (no) Pyrazinderivater
NO20071642L (no) N-Benzensulfonylsubstituerte anilino-pyrimidinanaloger
DK1392714T3 (da) Steroider som agonister for FXR
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20091409L (no) Pyridin-3-yl-derivater som immunmodulerende midler
NO20053794L (no) N-(1-benzyl-2-oxo-2-(1-piperazinyl) etyl)-1-piperidinkarboksamid-derivater og relaterte forbindelsers bruk som CGRP-antagonister for behandling av hodepine.
MXPA03005822A (es) Compuestos heterociclicos que tienen actividad antibacteriana, proceso para su preparacion y composiciones farmaceuticas que los contienen.
WO2007017728A3 (fr) Nouveaux composes heterocycliques
WO2005003087A3 (fr) Composes nouveaux utiles comme agents anti-bacteriens
ATE505462T1 (de) Neue biologischaktive molekü le
NO20063111L (no) Fremgangsmate for fremstilling av tiazolpyrimidiner
AU8811401A (en) Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient
DK1156058T3 (da) Fremgangsmåde til fremstilling af (E,Z) 3-(2-aminoethoxyimino)-androstan-6,17-dion og analoger deraf
ATE405588T1 (de) Analoge des somatostatin

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application